Replimune Group, Inc.

replimune.com

What Do They Do?

Develops oncolytic immunotherapy drug candidates for cancer patients, using engineered viruses intended to kill tumors and activate an immune response.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

Its therapies are intended for cancer patients; Replimune plans to commercialize approved products on its own in the United States and potentially with pharmaceutical or biotechnology partners in other geographies.

How Are They Changing?

Since the FY2026 annual report

Latest quarter: Q1 FY2027, the three months to Jun 30, 2026

Net income: ▼ −20% (Loss); vs −$86.7M in Q1 FY2026

Aug 14, 2026 FDA approves TUDRIQEV for melanoma; U.S. launch preparations begin TUDRIQEV with nivolumab is approved for adults with unresectable advanced cutaneous melanoma after progression on a PD-1 regimen; launch is anticipated within 60 days.

Comments